Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF COMMON SHARES

Further to the company's news release dated March 28, 2024, Helix BioPharma Corp. has closed the private placement of 12,766,667 common shares of the company at a price of 15 cents per common share for gross proceeds of $1,915,000.

The company intends to use the net proceeds of the private placement for working capital. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on Aug. 9, 2024, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 10 per cent of gross proceeds raised to an eligible finder.

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on its proprietary technological platform, DOS47. Helix is listed on the TSX under the symbol HBP.

We seek Safe Harbor.